- Home
- LEGN vs MDGL Comparison
LEGN vs MDGL Comparison
Compare LEGN & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- MDGL
- Stock Information
- Founded
- LEGN 2014
- MDGL 2011
- Country
- LEGN United States
- MDGL United States
- Employees
- LEGN N/A
- MDGL N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- LEGN Health Care
- MDGL Health Care
- Exchange
- LEGN Nasdaq
- MDGL Nasdaq
- Market Cap
- LEGN 5.4B
- MDGL 6.1B
- IPO Year
- LEGN 2020
- MDGL N/A
- Fundamental
- Price
- LEGN $38.80
- MDGL $302.17
- Analyst Decision
- LEGN Strong Buy
- MDGL Strong Buy
- Analyst Count
- LEGN 11
- MDGL 9
- Target Price
- LEGN $74.60
- MDGL $420.63
- AVG Volume (30 Days)
- LEGN 1.4M
- MDGL 371.3K
- Earning Date
- LEGN 08-11-2025
- MDGL 08-05-2025
- Dividend Yield
- LEGN N/A
- MDGL N/A
- EPS Growth
- LEGN N/A
- MDGL N/A
- EPS
- LEGN N/A
- MDGL N/A
- Revenue
- LEGN $728,303,000.00
- MDGL $317,383,000.00
- Revenue This Year
- LEGN $65.33
- MDGL $286.67
- Revenue Next Year
- LEGN $54.68
- MDGL $67.98
- P/E Ratio
- LEGN N/A
- MDGL N/A
- Revenue Growth
- LEGN 112.46
- MDGL N/A
- 52 Week Low
- LEGN $27.34
- MDGL $200.63
- 52 Week High
- LEGN $59.62
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- LEGN 47.38
- MDGL 48.85
- Support Level
- LEGN $38.53
- MDGL $286.44
- Resistance Level
- LEGN $45.30
- MDGL $312.05
- Average True Range (ATR)
- LEGN 1.76
- MDGL 14.84
- MACD
- LEGN -0.61
- MDGL -3.14
- Stochastic Oscillator
- LEGN 9.73
- MDGL 22.01
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.